Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.
After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.
One of the execs who masterminded Daiichi Sankyo's acquisition of Ranbaxy Laboratories--and then lived with it as the generic drugmaker drew the Japanese company into a whirlwind of regulatory issues--is stepping down as chairman.
In an effort to control costs, Japan's Daiichi Sankyo is reworking its manufacturing network and says that in Japan, it has even turned over some of its warehousing and logistics to another company.
Ranbaxy Laboratories continues to spend big as it tries to deal with regulatory issues at plants banned by the FDA, issues that pushed it into the arms of competitor Sun Pharmaceutical. The more than $20 million in write-downs on inventory and goodwill it had to take in the last quarter led to a loss, even as sales improved slightly.
Thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage. We thought we'd look into the products whose prices have increased the most since 2007, to see how and why their prices are leaping.
Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.
Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.
Daiichi Sankyo has found one way to deal with Ranbaxy Laboratories' persistent quality problems: Hand them off to somebody else to fix. That is what the Japanese drugmaker will do with an agreement to sell Ranbaxy to Sun Pharmaceutical in an all stock deal that will give Daiichi Sankyo a 9% stake in Sun.
Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.